(Reuters) - Valeant Pharmaceuticals (VRX.TO), which dropped a $5.7 billion offer for Cephalon Inc (CEPH.O) earlier this week, is talking to potential takeover targets and will pursue other large deals, its chief executive said on Tuesday.
CEO Michael Pearson said the Canadian drugmaker was looking at acquisitions of all sizes and that Valeant had the financial firepower to do a deal bigger than that of Cephalon.
